244 related articles for article (PubMed ID: 30717762)
41. Barrett's oesophagus.
Shaheen NJ; Richter JE
Lancet; 2009 Mar; 373(9666):850-61. PubMed ID: 19269522
[TBL] [Abstract][Full Text] [Related]
42. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
43. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
[TBL] [Abstract][Full Text] [Related]
44. Genetics and prevention of oesophageal adenocarcinoma.
Fitzgerald RC
Recent Results Cancer Res; 2005; 166():35-46. PubMed ID: 15648181
[TBL] [Abstract][Full Text] [Related]
45. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
46. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
47. Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus.
Gotovac JR; Kader T; Milne JV; Fujihara KM; Lara-Gonzalez LE; Gorringe KL; Kalimuthu SN; Jayawardana MW; Duong CP; Phillips WA; Clemons NJ
Cell Mol Gastroenterol Hepatol; 2021; 12(2):689-713. PubMed ID: 33774196
[TBL] [Abstract][Full Text] [Related]
48. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
49. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
[TBL] [Abstract][Full Text] [Related]
50. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of p53 protein in Barrett's syndrome with malignant transformation.
Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D
J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390
[TBL] [Abstract][Full Text] [Related]
52. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
[TBL] [Abstract][Full Text] [Related]
53. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
54. Can Genomic Sequencing Identify High-Risk Barrett's Esophagus Earlier Than Pathologists?
Stachler MD; Bass AJ
Cancer Cell; 2020 Nov; 38(5):626-628. PubMed ID: 33171128
[TBL] [Abstract][Full Text] [Related]
55. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
56. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.
Dighe SG; Chen J; Yan L; He Q; Gharahkhani P; Onstad L; Levine DM; Palles C; Ye W; Gammon MD; Iyer PG; Anderson LA; Liu G; Wu AH; Dai JY; Chow WH; Risch HA; Lagergren J; Shaheen NJ; Bernstein L; Corley DA; Prenen H; deCaestecker J; MacDonald D; Moayyedi P; Barr H; Love SB; Chegwidden L; Attwood S; Watson P; Harrison R; Ott K; Moebus S; Venerito M; Lang H; Mayershofer R; Knapp M; Veits L; Gerges C; Weismüller J; Gockel I; Vashist Y; Nöthen MM; Izbicki JR; Manner H; Neuhaus H; Rösch T; Böhmer AC; Hölscher AH; Anders M; Pech O; Schumacher B; Schmidt C; Schmidt T; Noder T; Lorenz D; Vieth M; May A; Hess T; Kreuser N; Becker J; Ell C; Ambrosone CB; Moysich KB; MacGregor S; Tomlinson I; Whiteman DC; Jankowski J; Schumacher J; Vaughan TL; Madeleine MM; Hardie LJ; Buas MF
Carcinogenesis; 2021 Apr; 42(3):369-377. PubMed ID: 33300568
[TBL] [Abstract][Full Text] [Related]
57. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
58. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
59. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
60. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
